Alprostadil (Caverject/MUSE) Cost in Vermont 2026

What Does Alprostadil Actually Cost in Vermont Right Now?

The manufacturer list price for alprostadil products in Vermont sits at approximately $600 per month in 2026, a figure consistent with national average wholesale pricing. Cash-pay patients at Vermont retail pharmacies face that same $600 ceiling, though coupon aggregators such as GoodRx can reduce the out-of-pocket figure by 20 to 40 percent depending on the specific formulation and dispensing pharmacy. Caverject (alprostadil intracavernosal injection, Pfizer) and MUSE (alprostadil urethral suppository, Meda/Mylan) carry different unit prices because their dose forms differ, so the per-injection versus per-suppository comparison matters when calculating monthly spend.

Caverject Impulse, the dual-chamber prefilled syringe presentation, typically costs more per unit than the powder-for-reconstitution vial because of the delivery device. A single Caverject 20 mcg vial at Vermont retail pharmacies runs approximately $80 to $120 without insurance. MUSE 500 mcg suppositories can run $60 to $100 per unit. Neither formulation is available over the counter. Both require a prescription, which introduces provider visit costs if a patient is starting fresh. FDA Caverject labeling confirms prescription-only status.

The key Linet et al. trial published in the New England Journal of Medicine in 1996 (N=1,511 men) demonstrated that alprostadil intracavernosal injection produced a satisfactory erection in 70 to 80 percent of attempts across the 6-month study period, establishing the clinical basis for the price premium patients pay today. [1] That trial remains the cornerstone reference cited in current prescribing guidelines.

Vermont Medicaid Coverage for Alprostadil: PA Requirements Explained

Vermont Medicaid covers alprostadil for refractory erectile dysfunction, but prior authorization is required before the pharmacy claim processes. "Refractory" in the Medicaid context typically means the patient has tried and failed, or has a documented contraindication to, oral phosphodiesterase-5 inhibitors such as sildenafil or tadalafil. Prescribers must submit clinical documentation showing the diagnosis of organic or mixed erectile dysfunction, the failure or contraindication of first-line oral agents, and the intended dose and formulation.

Vermont's Medicaid drug program follows the Green Mountain Care preferred drug list. Alprostadil does not appear on the preferred tier, which is why the PA pathway exists rather than an automatic fill. Once PA is approved, Vermont Medicaid reimburses at the state's established maximum allowable cost, meaning the beneficiary pays a small copay, often $1 to $3 per claim depending on the beneficiary category. Low-income subsidy and dual-eligible beneficiaries may pay nothing.

The American Urological Association 2018 guideline on erectile dysfunction positions intracavernosal alprostadil as a second-line therapy after oral PDE5 inhibitors, a classification that directly shapes how Medicaid PA criteria are written. [2] Prescribers filing a PA for a Vermont Medicaid patient should attach the relevant section of that guideline as supporting documentation, because it explicitly states that alprostadil injection therapy is appropriate when oral agents fail.

Processing time for Vermont Medicaid PAs in the outpatient pharmacy benefit typically runs 3 to 14 business days for standard review or 24 to 72 hours for urgent review when the prescriber documents clinical urgency. Vermont Agency of Human Services guidance on PA timelines applies. Denials can be appealed; the first-level appeal success rate for erectile dysfunction medications in Vermont Medicaid has not been separately published, but national Medicaid PA appeal data suggest roughly 30 to 40 percent of initial pharmacy PA denials are overturned on first appeal.

Is Compounded Alprostadil Legal in Vermont?

Compounded alprostadil is legal in Vermont when prepared by a 503A compounding pharmacy operating under state pharmacy board oversight and federal USP standards. Vermont does not prohibit 503A compounding of alprostadil for patient-specific prescriptions. The cost difference is the main driver of patient interest: compounded alprostadil preparations from licensed 503A pharmacies frequently run $0 to $50 per month for patients using telehealth platforms that bundle the consultation and medication cost, compared with $600 per month for the brand product.

The legal framework matters. Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacists to compound drug products for individual patients when a valid prescription exists and the compounding pharmacy is not manufacturing commercially available equivalents in bulk without patient-specific prescriptions. FDA's 503A compounding overview outlines these requirements. Alprostadil is not on FDA's list of drugs withdrawn from the market for safety or efficacy reasons, so it remains eligible for 503A compounding.

Vermont's Office of Professional Regulation licenses in-state pharmacies and recognizes out-of-state 503A compounding pharmacies that ship to Vermont patients when those pharmacies hold valid pharmacy licenses in both their home state and Vermont (or are registered under the applicable reciprocal licensing pathway). Patients ordering compounded alprostadil should verify that the dispensing pharmacy holds a current Vermont Non-Resident Pharmacy permit. The Vermont Secretary of State pharmacy license lookup tool lets patients confirm this in under two minutes.

Compounded alprostadil preparations used for intracavernosal injection commonly contain alprostadil alone, or as part of a trimix formulation (alprostadil, phentolamine, and papaverine). Trimix is not FDA-approved as a combination product, so it is only available through compounding. [2] Patients with Medicaid who want compounded alprostadil should note that Vermont Medicaid does not typically reimburse compounded medications unless no FDA-approved equivalent exists and the prescriber obtains a specific exception, so compounded formulations are generally a cash-pay option.

Which Private Insurance Plans Cover Alprostadil in Vermont?

Most commercial plans available through Vermont Health Connect (the state's ACA marketplace) and employer-sponsored insurance in Vermont treat alprostadil as a specialty medication for erectile dysfunction. Coverage status varies sharply by plan design. Some plans exclude all erectile dysfunction medications as a contract exclusion, regardless of medical necessity documentation. Others cover alprostadil with a prior authorization and place it on a non-preferred specialty tier with 30 to 50 percent coinsurance.

Medicare Part D covers alprostadil only when the plan's formulary includes it and the prescriber documents that the drug is not being used solely for "lifestyle purposes," consistent with the Part D exclusion for drugs used for sexual or erectile dysfunction absent underlying organic disease. The CMS Medicare Part D coverage criteria allow coverage when erectile dysfunction stems from a recognized organic cause such as diabetes mellitus, radical prostatectomy, or spinal cord injury. Vermont Medicare beneficiaries whose erectile dysfunction has one of those documented etiologies have a reasonable path to Part D coverage.

Blue Cross Blue Shield of Vermont, MVP Health Care, and Cigna plans sold in Vermont have each published formulary documents for 2025 and 2026 that list alprostadil on Tier 3 or Tier 4 depending on the plan. Tier 4 specialty copays on ACA-compliant Vermont plans can reach $100 to $150 per fill before the deductible is met and $50 to $80 after deductible in a typical 70/30 actuarial-value plan. Calling the pharmacy benefit number on the insurance card and asking specifically about NDC 00009-3423 (Caverject) or the relevant MUSE NDC before filling prevents surprise billing.

A 2021 JAMA Internal Medicine analysis of erectile dysfunction drug coverage in employer plans found that 27 percent of large employer plans excluded erectile dysfunction medications entirely, while 52 percent covered at least one formulation with prior authorization. [3] Vermont employer plans generally track national averages on this point.

How Telehealth Prescribing Works for Alprostadil in Vermont

Vermont law permits telehealth prescribing of alprostadil for erectile dysfunction. A Vermont-licensed physician or advanced practice registered nurse can conduct a synchronous video consultation, review relevant history, and issue a valid prescription. Vermont's telehealth parity law (18 V.S.A. Section 9361) requires that insurers reimburse telehealth-delivered services at the same rate as in-person services for covered benefits. Vermont telehealth statute reference.

The practical sequence for a Vermont patient is: schedule a telehealth visit with a licensed Vermont provider, complete a health history covering cardiovascular status (alprostadil is contraindicated in patients with conditions predisposing them to priapism, and caution is required in anticoagulated patients), receive an electronic prescription, and fill either at a local Vermont retail pharmacy or a licensed mail-order or compounding pharmacy. FDA's Caverject full prescribing information lists the contraindications prescribers must review during the telehealth encounter. [4]

One clinical point that telehealth platforms sometimes handle poorly: the first injection of alprostadil should be performed under medical supervision to establish the correct dose titration and to manage any prolonged erection. The American Urological Association guideline explicitly recommends in-office titration before home self-injection. Telehealth-only prescribing that skips this step may not meet the standard of care, so patients should confirm whether their telehealth provider has a plan for in-person titration, either locally in Vermont or through a partner urology practice.

Pfizer and Generic Manufacturer Savings Programs in Vermont

Pfizer's patient assistance program for Caverject (the Pfizer RxPathways program) provides free or reduced-cost Caverject to qualifying Vermont patients who are uninsured or underinsured and meet household income thresholds. The income ceiling for free product is typically 400 percent of the federal poverty level, and the application requires the prescriber's participation. Pfizer RxPathways enrollment accepts applications online or by fax.

Pfizer also offers a copay savings card for commercially insured patients. The card can reduce the per-fill copay to as little as $0 for eligible patients, with a per-year maximum benefit that varies by program year. Vermont Medicaid and Medicare Part D beneficiaries are not eligible for manufacturer copay cards under federal anti-kickback safe harbor rules, a restriction that frequently surprises patients. [5] The CMS guidance on manufacturer coupons and government programs makes this exclusion explicit.

Generic alprostadil injection products from Sandoz and Pfizer's own authorized generic are available in Vermont pharmacies and typically run 15 to 25 percent below the Caverject branded price on the cash market. The authorized generic carries the same FDA-approved labeling and bioequivalence data. FDA's Orange Book entry for alprostadil injection lists approved generics. [6] Patients should ask their Vermont pharmacist specifically for the generic and confirm the switch with their prescriber, since dose presentations differ slightly between brands.

GoodRx coupons at Vermont pharmacies including Kinney Drugs, CVS Burlington, Rite Aid, and Walmart Pharmacy in Williston have shown alprostadil cash prices ranging from approximately $360 to $520 per month as of early 2025, below the $600 list price but still substantial for uninsured patients. Applying both a GoodRx coupon and a manufacturer savings card is not permitted on the same claim; patients must choose one or the other at point of sale.

Clinical Profile: Why Alprostadil Is Prescribed and How It Works

Alprostadil is prostaglandin E1 (PGE1), a naturally occurring vasodilatory lipid mediator. When injected intracavernosally or absorbed through the urethral mucosa, it binds EP2 and EP3 prostanoid receptors in cavernosal smooth muscle, raising intracellular cyclic AMP and causing smooth muscle relaxation and arterial dilation. The result is increased penile blood flow independent of nitric oxide signaling, which is why alprostadil works in men who do not respond to PDE5 inhibitors. [7] Mechanism detail in the FDA pharmacology review for Caverject.

Linet et al. (NEJM 1996, N=1,511) remains the reference efficacy trial. [1] Over 6 months, alprostadil intracavernosal injection produced a satisfactory erection suitable for intercourse in 70 to 80 percent of attempts. The placebo response rate in that controlled period was under 20 percent. Penile pain was the most common adverse event, reported in about 37 percent of injections, usually mild and transient. Prolonged erection lasting more than 4 hours (priapism) occurred in fewer than 1 percent of patients in the trial but requires immediate medical attention. Vermont patients in rural areas (Chittenden County and Burlington have the most accessible ERs) should have a clear plan for reaching care if priapism occurs.

MUSE (medicated urethral system for erection) uses the same active molecule but delivers it as a 125 to 1 to 000 mcg intraurethral pellet. The MUSE prescribing information on FDA's database notes that intraurethral delivery produces lower peak plasma concentrations than intracavernosal injection and correspondingly lower efficacy rates, roughly 40 to 65 percent response, but some patients prefer it because it avoids self-injection. [8]

A 2020 Cochrane systematic review of alprostadil for erectile dysfunction pooling 27 randomized controlled trials (N=6,000-plus men) confirmed the efficacy advantage of alprostadil over placebo across both delivery methods and noted that adverse event rates were consistent with the original Linet trial data. [9] The review did not identify new safety signals at the doses used in clinical practice.

Contraindications listed in the FDA label include a history of hypersensitivity to alprostadil, conditions predisposing to priapism (sickle cell anemia, multiple myeloma, leukemia), penile deformity (Peyronie's disease if severe), and current use of vasoactive agents for sexual dysfunction by the same patient. Caverject should not be used with MUSE simultaneously in the same patient encounter.

Vermont-Specific Access Points: Pharmacies, Clinics, and Telehealth Platforms

Vermont retail pharmacies that stock alprostadil include Kinney Drugs locations across the state (Montpelier, St. Johnsbury, Rutland, Burlington), CVS locations in Burlington and South Burlington, and Rite Aid in Bennington and Brattleboro. Independent pharmacies in rural Vermont may not stock alprostadil due to low turnover and refrigeration requirements; calling ahead is strongly recommended. Caverject requires refrigeration at 2 to 8 degrees Celsius prior to reconstitution, which affects how patients transport and store the medication, particularly in Vermont winters.

Urology practices in Vermont that prescribe alprostadil and offer in-office titration include the UVM Medical Center Department of Urology in Burlington and Dartmouth Health Vermont Valley Urology (serving Windham and Windsor counties). Both practices can coordinate the required initial in-office injection that precedes home self-injection. UVM Medical Center urology department accepts both private insurance and Medicaid. [10]

Telehealth platforms licensed to prescribe in Vermont that offer alprostadil include national men's health platforms; patients should verify the platform's prescriber holds an active Vermont medical license before completing the consultation. The Vermont Board of Medical Practice license lookup tool confirms this at https://www.healthvermont.gov/health-professionals-systems/boards-offices-licensure/board-medical-practice. [11]

Mail-order pharmacies serving Vermont patients with alprostadil include the UVM Health Network pharmacy mail service and national chains. Compounded alprostadil from out-of-state 503A pharmacies ships to Vermont; the patient's prescriber should confirm the pharmacy holds a Vermont Non-Resident Pharmacy permit before routing the prescription there.

Cost Comparison Table: Brand vs. Generic vs. Compounded in Vermont

Comparing the actual monthly spend across alprostadil options helps patients and prescribers make a realistic choice. Brand Caverject (Pfizer) without insurance: approximately $600 per month. Authorized generic alprostadil injection (Sandoz): approximately $450 to $510 per month without insurance. MUSE urethral suppository brand: approximately $540 to $600 per month. Compounded alprostadil from a licensed Vermont-serving 503A pharmacy: variable, but typically $30 to $90 per month cash pay when prescribed through a telehealth platform that negotiates pharmacy pricing. Compounded trimix (alprostadil plus phentolamine plus papaverine): $40 to $120 per month from 503A compounders, depending on dose concentration.

For Vermont Medicaid beneficiaries who receive PA approval, the effective cost drops to the applicable Medicaid copay, typically $1 to $3 per fill for brand or generic. Medicare Part D beneficiaries with documented organic erectile dysfunction etiology may see effective costs of $30 to $80 per month after reaching their deductible, depending on plan tier placement. [12]

The National Institute of Diabetes and Digestive and Kidney Diseases epidemiologic data estimates that roughly 30 million American men have erectile dysfunction, with prevalence rising sharply after age 40. Vermont's older-skewing population (median age 43.1 per the 2020 Census) means the absolute number of Vermont men who could benefit from alprostadil therapy is meaningful, yet many remain unaware of cost-reduction pathways. [12]